



Press release

ENYO PHARMA announces completion of series C financing with VESALIUS BIOCAPITAL

*And continued progress of its alpestria-1 clinical phase 2 study in alport
syndrome patient*

- **ENYO completes €32 million Series C** with new €6 million investment from Vesalius Biocapital IV
- **New funds will support two additional clinical studies** and expand preclinical research, including in ADPKD
- **Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor** in Alport Syndrome confirmed for Q4 2025

Lyon, France – June 12, 2025 – ENYO Pharma (“ENYO”), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases, today announced the smooth continuation of its Phase 2 ALPESTRIA-1 trial in 26 Alport syndrome patients. The topline results from the trial are on track for the fourth quarter of 2025. In parallel, ENYO has finalized its Series C financing round with a €6 million investment from [Vesalius Biocapital IV](#), bringing the total **Series C raise to €32 million**.

The ongoing ALPESTRIA-1 study evaluates Vonafexor, a highly selective and oral FXR agonist, in patients with Alport syndrome, a rare genetic kidney disease with no approved therapy. The trial involves a 24-week ascending doses regimen followed by a 12-week off-treatment observation period. ALPESTRIA-1 was launched mid 2024 in 4 countries (US, F, SP and D) following Orphan Drug Designation from both the FDA and EMA.

The new funding from Vesalius Biocapital IV extends ENYO’s cash runway through the **second half of 2026** and enables the initiation of two new clinical programs:

- **A proof-of-concept trial** in patients with **Chronic Kidney Disease (CKD)** grade 3 and concurrent **F2/F3 MASH**, building on the promising renal results from the previous **Phase 2 LIVIFY clinical study**;

- **A PK/PD head-to-head comparison** of Vonafoxor and its analog **EYP651** in healthy subjects.

In addition, ENYO will continue to expand its **preclinical portfolio**, notably in **Autosomal Dominant Polycystic Kidney Disease (ADPKD)**, where the Vonafoxor franchise could offer a novel and disease-modifying approach.

*“We are pleased with the continued progress of ALPESTRIA-1 and honored to welcome **Vesalius Biocapital** to our investor syndicate and **Dr. Jean-Christophe Renondin** as new Board member,” said **Dr. Jacky Vonderscher, CEO of ENYO**. “This additional investment will allow us to accelerate the development of our FXR agonist pipeline in both rare and more prevalent kidney diseases. We share a common belief with Vesalius in the transformative potential of Vonafoxor and EYP651 for patients suffering from inflammation- and fibrosis-driven renal conditions”.*

*“**Vesalius Biocapital** is excited to support ENYO as it progresses into the next phase of clinical development for **Vonafoxor and its analog EYP651**,” commented **Dr. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV**. “There is an immense need for new treatments in kidney conditions such as Alport Syndrome and CKD. We believe Vonafoxor has the potential to help these patients and make a meaningful impact on their lives. I look forward to working with ENYO’s excellent leadership team to advance this promising therapeutic candidate.”*

About ENYO PHARMA

ENYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis/transplantation for patients with rare and common kidney diseases.

Since its inception ENYO collected extensive phase I/II clinical data through nine completed clinical studies with ca. 400 subjects.

ENYO is supported by a strong syndicate of global investors: OrbiMed, Morningside, AndEra, BPIFrance (InnoBio and Large Venture), Sofinnova Partners and Vesalius). For more information: [ENYO Pharma](#)

A propos de Vesalius Biocapital :

[Vesalius is a specialist life sciences venture capital investor](#), investing in companies in later stage companies in drug development, medical device diagnostic and e-health since 2007.

Vesalius Biocapital IV, launched in June 2023, targets first and best-in-class European life science companies in drug development and digital health.

Its investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs.

The team is based in Europe to explore investment opportunities and valuation potential for the portfolio. Managing Partners include **Guy Geldhof, Dr Jean-Christophe Renondin and Stéphane Verdood**.

CONTACTS :

ENYO Pharma Investor Relations

+33 (0)4 37 70 02 27

communication@enyopharma.com

Media Relations

Annie-Florence Loyer, NewCap Media

+33 (0)1 44 71 00 12/ +33 (0)6 88 20 35 59

afloyer@newcap.fr